{
    "clinical_study": {
        "@rank": "63776", 
        "arm_group": [
            {
                "arm_group_label": "Coenzyme Q10 & Atorvastatin", 
                "arm_group_type": "Experimental", 
                "description": "10 mg Atorvastatin daily plus  100 mg Coenzyme Q10 pearl supplement twice daily for four months."
            }, 
            {
                "arm_group_label": "Atorvastatin & placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "10 mg Atorvastatin daily and the placebo of Coenzyme Q10 pearl for four months."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to compare the effect of addition of combination of\n      Atorvastatin/CoenzymeQ10 to standard congestive heart failure (CHF) treatment versus\n      addition of Atorvastatin alone on CHF outcomes."
        }, 
        "brief_title": "Atorvastatin/CoenzymeQ10 in Congestive Heart Failure", 
        "condition": "Congestive Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Documented Congestive hear failure\n\n          -  Ejection Fraction less than 40 percent\n\n          -  Compensated heart failure without hospital admission during previous three months\n\n          -  No change in type and dose of medications in the last months\n\n          -  New York Heart Association Function Class 2 to 4\n\n        Exclusion Criteria:\n\n          -  Acute coronary syndrome developing in the last month\n\n          -  Active myocarditis\n\n          -  Active pericarditis\n\n          -  Uncontrolled hypertension\n\n          -  Hepatic failure(Child B,C)\n\n          -  Pulmonary failure\n\n          -  Renal failure\n\n          -  Heart failure with KILLIP classification 3 and 4"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01925937", 
            "org_study_id": "392219"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Coenzyme Q10 & Atorvastatin", 
                    "Atorvastatin & placebo"
                ], 
                "intervention_name": "Atorvastatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Coenzyme Q10 & Atorvastatin", 
                "intervention_name": "Coenzyme Q10", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Atorvastatin & placebo", 
                "intervention_name": "placebo for coenzyme Q10", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Coenzyme Q10", 
                "Ubiquinone", 
                "Atorvastatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "keyword": [
            "Coenzyme Q10", 
            "Atorvastatin", 
            "clinical trial", 
            "congestive heart failure"
        ], 
        "lastchanged_date": "August 16, 2013", 
        "location": {
            "contact": {
                "email": "nemati@med.mui.ac.ir", 
                "last_name": "Amin Nemati, MD", 
                "phone": "00989131009918"
            }, 
            "facility": {
                "address": {
                    "city": "Isfahan", 
                    "country": "Iran, Islamic Republic of", 
                    "zip": "8174673461"
                }, 
                "name": "Vice Chancellery for Research of Isfahan University of Medical Sciences, Isfahan, Iran"
            }, 
            "investigator": {
                "last_name": "Javad Shahabi, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "nemati@med.mui.ac.ir", 
            "last_name": "Amin Nemati, MD", 
            "phone": "00989131009918"
        }, 
        "overall_official": {
            "affiliation": "Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.", 
            "last_name": "Masoud Pourmoghaddas, cardiologist", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "For the determination of change in EF,cardiac EF was determined two times . Baseline :at  the beginning of study(before intervention)  and the second time after 4 months(after intervention).", 
            "measure": "Change in cardiac Ejection Fraction (EF)", 
            "safety_issue": "No", 
            "time_frame": "Baseline for the first time  and after 4 months for the second time"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01925937"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Isfahan University of Medical Sciences", 
            "investigator_full_name": "Amin Nemati", 
            "investigator_title": "member of Isfahan Medical Students Research Committee", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "For the determination of change in New York Heart Association Function Class.it  was determined two times .Baseline:at  the beginning of study(before intervention)and the second time after 4 months(after intervention).", 
            "measure": "Change in New York Heart Association Function Class", 
            "safety_issue": "No", 
            "time_frame": "Baseline for the first time and after 4 months for the second time"
        }, 
        "source": "Isfahan University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Isfahan University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}